ホーム>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Methyltransferase>>WDR5-IN-1

WDR5-IN-1

カタログ番号GC62558

WDR5-IN-1 は、強力で選択的な WD リピート ドメイン 5 (WDR5) 阻害剤であり、Kd は <0.02 nM です。 WDR5-IN-1 は、2.2 nM の IC50 で MLL1 ヒストンメチルトランスフェラーゼ (HMT) 活性を阻害します。 WDR5-IN-1 は、WDR5 置換遺伝子での MYC 動員を減少させ、CHP-134 (神経芽細胞腫) および Ramos (バーキットリンパ腫) 株で強力な抗増殖効果を示します。

Products are for research use only. Not for human use. We do not sell to patients.

WDR5-IN-1 化学構造

Cas No.: 2408842-51-1

サイズ 価格 在庫数 個数
5 mg
$450.00
在庫あり
10 mg
$792.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

WDR5-IN-1 is a potent and selective WD repeat domain 5 (WDR5) inhibitor, with a Kd of <0.02 nM. WDR5-IN-1 inhibits MLL1 histone methyltransferase (HMT) activity with an IC50 of 2.2 nM. WDR5-IN-1 diminishes MYC recruitment at WDR5-displaced genes and exhibits potent anti-proliferative effects in CHP-134 (neuroblastoma) and Ramos (Burkitt’s lymphoma) lines[1].

WDR5-IN-1 (1 µM; 48 hours) shows an apparent decrease in G2M phase cells[1].WDR5-IN-1 (0.01-3 µM; 24-48 hours) increases p53 and p21 protein levels[1].WDR5-IN-1 shows anti-proliferative activity in MYC-driven cancers (CHP-134, Ramos, Raji, Daudi, SW620, SW480 cells), with GI50s ranging from 0.26-3.2 µM[1].

[1]. Tian J, et al.Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.J Med Chem. 2020 Jan 23;63(2):656-675.

レビュー

Review for WDR5-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for WDR5-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.